BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33369676)

  • 1. Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS.
    Zhao SS; Jones GT; Macfarlane GJ; Hughes DM; Moots RJ; Goodson NJ
    Rheumatology (Oxford); 2021 Sep; 60(9):4158-4165. PubMed ID: 33369676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials?
    Jones GT; Dean LE; Pathan E; Hollick RJ; Macfarlane GJ
    Ann Rheum Dis; 2020 Jul; 79(7):914-919. PubMed ID: 32327428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
    Micheroli R; Tellenbach C; Scherer A; Bürki K; Niederman K; Nissen MJ; Zufferey P; Exer P; Möller B; Kyburz D; Ciurea A
    Ann Rheum Dis; 2020 Sep; 79(9):1203-1209. PubMed ID: 32581090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis.
    Zhao SS; Yoshida K; Jones GT; Hughes DM; Duffield SJ; Tedeschi SK; Lyu H; Moots RJ; Solomon DH; Goodson NJ
    Arthritis Res Ther; 2019 Jul; 21(1):177. PubMed ID: 31331375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Smoking in Response to Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Methodologic Considerations for Longitudinal Observational Studies.
    Zhao SS; Yoshida K; Jones GT; Hughes DM; Tedeschi SK; Lyu H; Moots RJ; Solomon DH; Goodson NJ
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):591-599. PubMed ID: 30762311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
    Ørnbjerg LM; Brahe CH; Askling J; Ciurea A; Mann H; Onen F; Kristianslund EK; Nordström D; Santos MJ; Codreanu C; Gómez-Reino J; Rotar Z; Gudbjornsson B; Di Giuseppe D; Nissen MJ; Pavelka K; Birlik M; Kvien T; Eklund KK; Barcelos A; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Loft AG; van der Horst-Bruinsma I; Jones G; Iannone F; Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
    Ann Rheum Dis; 2019 Nov; 78(11):1536-1544. PubMed ID: 31431486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
    Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
    Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.
    Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Lindström U; Pavelka K; Yilmaz N; Favalli EG; Nissen MJ; Michelsen B; Vieira-Sousa E; Jones GT; Ionescu R; Relas H; Sanchez-Piedra C; Tomšič M; Geirsson AJ; van der Horst-Bruinsma I; Askling J; Loft AG; Nekvindova L; Direskeneli H; Iannone F; Ciurea A; Fagerli KM; Santos MJ; Macfarlane GJ; Codreanu C; Eklund K; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Rusman T; Østergaard M; Hetland ML
    J Rheumatol; 2023 Aug; 50(8):1009-1019. PubMed ID: 36455943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry.
    Fröhlich F; Micheroli R; Hebeisen M; Kissling S; Bürki K; Exer P; Bräm R; Niedermann K; Möller B; Nissen MJ; Kyburz D; Andor M; Distler O; Scherer A; Ciurea A
    Clin Rheumatol; 2023 May; 42(5):1267-1274. PubMed ID: 36574181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extremely poor patient-reported outcomes are associated with lack of clinical response and decreased retention rate of tumour necrosis factor inhibitor treatment in patients with axial spondyloarthritis.
    Krabbe S; Glintborg B; Østergaard M; Hetland ML
    Scand J Rheumatol; 2019 Mar; 48(2):128-132. PubMed ID: 30102111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatigue in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Analysis from a Longitudinal Observation Cohort.
    Bedaiwi M; Sari I; Thavaneswaran A; Ayearst R; Haroon N; Inman RD
    J Rheumatol; 2015 Dec; 42(12):2354-60. PubMed ID: 26523020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis.
    Bekele DI; Cheng E; Reimold A; Geier C; Ganuthula K; Walsh JA; Clegg DO; Dubreuil M; Kaushik P; Ng B; Chang E; Duong R; Park J; Kerr GS
    Rheumatol Int; 2022 Nov; 42(11):1925-1937. PubMed ID: 34724089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
    Micheroli R; Hebeisen M; Wildi LM; Exer P; Tamborrini G; Bernhard J; Möller B; Zufferey P; Nissen MJ; Scherer A; Ciurea A;
    Arthritis Res Ther; 2017 Jul; 19(1):164. PubMed ID: 28724442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
    Nissen M; Delcoigne B; Di Giuseppe D; Jacobsson L; Hetland ML; Ciurea A; Nekvindova L; Iannone F; Akkoc N; Sokka-Isler T; Fagerli KM; Santos MJ; Codreanu C; Pombo-Suarez M; Rotar Z; Gudbjornsson B; van der Horst-Bruinsma I; Loft AG; Möller B; Mann H; Conti F; Yildirim Cetin G; Relas H; Michelsen B; Avila Ribeiro P; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Askling J; Glintborg B; Lindström U
    Rheumatology (Oxford); 2022 Nov; 61(12):4741-4751. PubMed ID: 35323903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comorbidity burden in axial spondyloarthritis: a cluster analysis.
    Zhao SS; Radner H; Siebert S; Duffield SJ; Thong D; Hughes DM; Moots RJ; Solomon DH; Goodson NJ
    Rheumatology (Oxford); 2019 Oct; 58(10):1746-1754. PubMed ID: 31220322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
    Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
    Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis.
    Hernández-Breijo B; Plasencia-Rodríguez C; Navarro-Compán V; Martínez-Feito A; Jochems A; Kneepkens EL; Wolbink GJ; Rispens T; Diego C; Pascual-Salcedo D; Balsa A
    Arthritis Res Ther; 2019 Feb; 21(1):66. PubMed ID: 30786913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.